Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : US authorities probing Emergent BioSolutions over COVID-19 vaccine issues - filing

07/30/2021 | 10:42am EDT
FILE PHOTO: A woman holds a test tube in front of displayed Emergent logo in this illustration

WASHINGTON, July 30 (Reuters) - Drug manufacturer Emergent BioSolutions Inc said on Friday it has received inquiries and subpoenas from a swathe of U.S. authorities related to its abilities to manufacture COVID-19 bulk drug substance.

Emergent came under regulatory scrutiny after an error led to millions of vaccine doses being ruined at its manufacturing facility in Baltimore, which was producing bulk drug substance for Johnson & Johnson's COVID-19 vaccine.

The U.S. Food and Drug Administration (FDA) in April halted operations at the plant after it discovered that ingredients from AstraZeneca's COVID-19 vaccine, also being produced there at that time, contaminated a batch of J&J's vaccines.

Emergent in a filing https://investors.emergentbiosolutions.com/node/20661/html on Friday said it has received "preliminary inquiries and subpoenas to produce documents" from the lawmakers, the Department of Justice, the Securities and Exchange Commission, the Financial Industry Regulatory Authority, and Maryland and New York Attorneys General.

The Department of Justice declined to comment on the matter.

Emergent said it was producing and has produced documents as required in response and will continue to cooperate with the government inquiries.

An FDA inspection in April turned up a long list of sanitary problems and bad manufacturing practices at the facility, including failure to train personnel to avoid cross contamination of COVID-19 vaccines from J&J and AstraZeneca.

Emergent said on Wednesday production at the Baltimore facility will now resume, following remedial actions, additional reviews and collaboration with the FDA and its manufacturing partners.

An FDA spokesperson said on Thursday the facility has not yet received any authorization for a COVID-19 vaccine, but may produce vaccine substance in advance of future inspections by the health regulator. (Reporting by Chris Prentice in Washington and Manojna Maddipatla in Bengaluru; Editing by Bernard Orr and Shounak Dasgupta)

© Reuters 2021
All news about ASTRAZENECA PLC
12:12pASTRAZENECA : Enhertu demonstrated clinically meaningful and durable response in..
12:06pASTRAZENECA : ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically..
10:09aLATEST : FDA panel to offer recommendations on booster shots
09:18aASTRAZENECA : EMA Fails To Find Link Between Blood Clots, AstraZeneca's Vaccine
08:23aASTRAZENECA : Says Imfinzi-Oleclumab Combination Improved Clinical Outcomes for ..
08:06aJOHNSON & JOHNSON : GSA Director Lauded for Luring More People to Get Covid-19 V..
07:31aASTRAZENECA : EU unsure if women face higher risk of clots from AstraZeneca shot
07:31aASTRAZENECA : IMFINZI Combined With Novel Immunotherapies Improved Clinical Outc..
07:11aASTRAZENECA : Buy rating from Morgan Stanley
06:57aASTRAZENECA : EU fails to confirm if women, young adults at higher clot risk fro..
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 214 M - -
Net income 2021 4 990 M - -
Net Debt 2021 24 654 M - -
P/E ratio 2021 31,5x
Yield 2021 2,51%
Capitalization 174 B 174 B -
EV / Sales 2021 5,64x
EV / Sales 2022 4,56x
Nbr of Employees 76 100
Free-Float 96,3%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Last Close Price 112,31 $
Average target price 136,08 $
Spread / Average Target 21,2%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC11.16%173 735
JOHNSON & JOHNSON4.98%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.21.62%249 329
NOVO NORDISK A/S51.34%233 887